Research programme: human monoclonal antibodies - ImmunoGen/Raven
Alternative Names: Human monoclonal antibodies research programme - Immunogen/RavenLatest Information Update: 15 Feb 2024
Price :
$50 *
At a glance
- Originator Raven biotechnologies
- Developer ImmunoGen; Raven biotechnologies
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 08 Sep 2003 Discontinued - Preclinical for Ovarian cancer in USA (unspecified route)
- 30 Apr 2001 Preclinical development for Ovarian cancer in USA (Unknown route)